All News
RA-ILD: an update
Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.
Read Article
Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4
Richard Conway RichardPAConway ( View Tweet)
Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk
Richard Conway RichardPAConway ( View Tweet)
Day 2: Tips to avoid burnout. I know it’s Sunday morning but a dose of #physicalactivity will keep the mind and body sane. Dare to accept challenge? #ACRVirtual5K Run #ACR22 #rheumatologyrunners #wellbeing #foggy @RheumNow #RheumPix https://t.co/N9ulz8KPVw
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539 https://t.co/mb3Eof2Uiv https://t.co/3i3ZTY25ru
Richard Conway RichardPAConway ( View Tweet)
Rech et al. 18 month results of ARIAA, 6 months abatacept in pre-RA, 1 year drug-free follow-up. 35% vs 65% developed RA. MRI response 57% vs 29%. @RheumNow #ACR22 Abstr#0530 https://t.co/35M2sPkIbW https://t.co/S8K39jkCh0
Richard Conway RichardPAConway ( View Tweet)
Ab0675 #ACR22 DAH in APLS
61 pts w APS, incident DAH
85% h/o VTE, 51% thrombocyt 43% valvulopathy
74% were on a/c at time of DAH
Relapse rate: 41% at 1 yr, 26% w/in 6 mos!!!
Risks: triple pos, thrombocyt, IVIG, PLEX, ventilation
Mortality 19% 1 yr, 38% 5 yrs
@RheumNow #ACRBest https://t.co/g1uz2Giilc
Eric Dein ericdeinmd ( View Tweet)
Ab0676 #ACR22 Adrenal hemorrhage in APLS
59 pts from SLE cohort + 181 from lit review
65% prior VTE, 12% CVA, 24% OB morbidity
46% thrombocyt, 21% had SLE
58% on a/c
69% b/l hemorrhage
63% adrenal insuff
Radiol remission: 6% at 1 yr, 41% at 5yr
Death 2% 1 yr, 11% at 5
@RheumNow https://t.co/EacifcN7Sd
Eric Dein ericdeinmd ( View Tweet)
Ab0683 #ACR22
aPL Pts ANA pos vs neg:
521 pts with +aPL Ab WO other autoimmune disease
224 +ANA, 297 -ANA
ANA+ ass w/ hemolytic anemia, thrombocyt, leukopenia, livedo, unexplained fetal death
Trend for arthritis, aPL nephropathy
@RheumNow https://t.co/3NHGymyL1C
Eric Dein ericdeinmd ( View Tweet)
Ab0685 #ACR22 APLS and prior COVID infection
TKR patients at HSS:
1/5 of patients had positive aPL Ab, mostly low level aCL IgM
Not associated with COVID infection or SARS-CoV-2 Ab
@RheumNow https://t.co/HJpnUOrrxc
Eric Dein ericdeinmd ( View Tweet)
Schieir et al. Women with early RA less likely to achieve remission. 12 months 37% vs 43%. 4 years 61% vs 64%. Time to remission 19 months vs 16 months. @RheumNow #ACR22 Abstr#0532 https://t.co/ZRuqqaPHHU https://t.co/pDBHHtLEhs
Richard Conway RichardPAConway ( View Tweet)
🧨Late breaking abstract🧨 #ACR22 @RheumNow #ACRbest
Identifying fetal myocardial targets in congenital heart block (CHB)
Abstract #L13
🫀maternal serum underwent mass spec. that identified Ab to 4 protein targets that predicted CHB including anti-ATP1A1 as early as 7w
Catherine Sims, MD DrCassySims ( View Tweet)
Porter et al. Asymptomatic Pre-RA to symptomatic Pre-RA to early RA steady increase in bacterial infection compared to HC. Causality or Reverse Causality? I think more likely reverse - disease related immunosuppresion @RheumNow #ACR22 Abstr#0535 https://t.co/i5iN3Db7rf https://t.co/2ynYF7Vqbl
Richard Conway RichardPAConway ( View Tweet)
Ab0674 #ACR22 HIT AND APLS??
Retrosp review of 23 pts treated for HIT in the hospital with APLS or SLE with aPL Ab:
Not one ultimately met clinical criteria for HIT
1 pt had PF4 antibodies, SRA testing negative in ALL cases
Thrombocytopenia w/ aPL Abs? Think APS 1st!
@Rheumnow https://t.co/ZYZP5VZF0R
Eric Dein ericdeinmd ( View Tweet)
Ab0673 #ACR22 Occurrence & Severity of ITP w or w/o APLS antibodies
Fewer bleeding events in ITP patients w/ aPL antibodies (15% vs 43%) compared to w/o aPL antibodies
Despite more use of a/c and lower median patients in aPL patients
Is aPL Ab a good prognosis for ITP?
@RheumNow https://t.co/yLBVUN2T0L
Eric Dein ericdeinmd ( View Tweet)
Hear Dr. @AngusWorthing discuss advocacy and more legislative updates at #ACR22 @RheumNow https://t.co/zD8xpcCzi2
Dr. Rachel Tate uptoTate ( View Tweet)
IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in
◦ total spinal pain (SP)
◦ nocturnal SP
◦ morning stiffness (BASDAI)
◦ fatigue (FACIT-F)
Deodhar et al, BE MOBILE 1,2 Abst 0409 https://t.co/vpCrG2COuB
#ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Fava et al. Urinary biomarkers at 3 months better than UPCR in predicting 12 month treatment response in SLE nephritis . CD163 AUC 0.83 vs 0.75 for UPCR @THKC1 @RheumNow #ACR22 Abstr#0536 https://t.co/YI3JC2uKcv https://t.co/jnkfbI0Z1M
Richard Conway RichardPAConway ( View Tweet)
Here is a quick recap on #ACR22 Abstr#0355 Effect of voclosporin in class V lupus nephritis #lupus https://t.co/0cR8On5UWN via @YouTube @RheumNow https://t.co/E25so6X2fj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Wilson et al. Sputum ACPA or RF assoc RA development in serum ACPA+ individuals. x4 more likely - 46% vs 12%. @RheumNow #ACR22 Abstr#0533 https://t.co/7kpeXWjeKI https://t.co/Sx41DOJAAX
Richard Conway RichardPAConway ( View Tweet)